SG11202110036RA - Method of making lipid-encapsulated rna nanoparticles - Google Patents

Method of making lipid-encapsulated rna nanoparticles

Info

Publication number
SG11202110036RA
SG11202110036RA SG11202110036RA SG11202110036RA SG11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA SG 11202110036R A SG11202110036R A SG 11202110036RA
Authority
SG
Singapore
Prior art keywords
rna nanoparticles
encapsulated rna
making lipid
lipid
making
Prior art date
Application number
SG11202110036RA
Inventor
Priya Karmali
Padmanabh Chivukula
Joseph Payne
Yanjie Bao
Original Assignee
Arcturus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcturus Therapeutics Inc filed Critical Arcturus Therapeutics Inc
Publication of SG11202110036RA publication Critical patent/SG11202110036RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
SG11202110036RA 2019-03-19 2020-03-18 Method of making lipid-encapsulated rna nanoparticles SG11202110036RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962820496P 2019-03-19 2019-03-19
PCT/US2020/023442 WO2020191103A1 (en) 2019-03-19 2020-03-18 Method of making lipid-encapsulated rna nanoparticles

Publications (1)

Publication Number Publication Date
SG11202110036RA true SG11202110036RA (en) 2021-10-28

Family

ID=72515073

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110036RA SG11202110036RA (en) 2019-03-19 2020-03-18 Method of making lipid-encapsulated rna nanoparticles

Country Status (11)

Country Link
US (3) US11737979B2 (en)
EP (1) EP3942050A4 (en)
JP (1) JP7678758B2 (en)
KR (1) KR20220018960A (en)
CN (1) CN113840926A (en)
AU (1) AU2020241756A1 (en)
BR (1) BR112021018526A2 (en)
CA (1) CA3133858A1 (en)
IL (1) IL286424A (en)
SG (1) SG11202110036RA (en)
WO (1) WO2020191103A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3981437T (en) 2014-04-23 2025-01-15 Modernatx Inc Nucleic acid vaccines
HUE059127T2 (en) 2015-10-22 2022-10-28 Modernatx Inc Respiratory virus vaccines
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. Influenza vaccine
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
US11980673B2 (en) 2018-10-09 2024-05-14 The University Of British Columbia Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
EP3866825A1 (en) * 2018-10-19 2021-08-25 Translate Bio, Inc. Pumpless encapsulation of messenger rna
CA3122080A1 (en) 2018-12-06 2020-06-11 Arcturus Therapeutics, Inc. Compositions and methods for treating ornithine transcarbamylase deficiency
SG11202110036RA (en) 2019-03-19 2021-10-28 Arcturus Therapeutics Inc Method of making lipid-encapsulated rna nanoparticles
EP4114470A4 (en) 2020-03-03 2024-04-17 Arcturus Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY
US11744887B2 (en) 2020-03-09 2023-09-05 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
WO2021205077A1 (en) 2020-04-09 2021-10-14 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CN116171150A (en) 2020-08-14 2023-05-26 阿克丘勒斯治疗公司 Method for lyophilizing lipid nanoparticles
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CN112999360B (en) * 2021-04-02 2023-01-06 四川大学 Use of DMP nanoparticles in mRNA delivery
WO2022235935A2 (en) * 2021-05-06 2022-11-10 Arcturus Therapeutics, Inc. Ionizable cationic lipids for rna delivery
WO2023014649A1 (en) * 2021-08-02 2023-02-09 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
JP2024546431A (en) * 2021-11-11 2024-12-24 アークトゥラス・セラピューティクス・インコーポレイテッド Ionizable Cationic Lipids for RNA Delivery
CN114471217A (en) * 2022-04-02 2022-05-13 深圳市瑞吉生物科技有限公司 Convection mixing device and method for liposome synthesis
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024030369A1 (en) * 2022-08-01 2024-02-08 Modernatx, Inc. Extraction-less reverse phase (rp) chromatography for mrna purity assessment
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN118236344A (en) * 2022-12-15 2024-06-25 深圳瑞吉生物科技有限公司 A nucleic acid lipid nanocarrier and its preparation method and application
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
WO2025005222A1 (en) * 2023-06-29 2025-01-02 国立大学法人大阪大学 Apparatus and method for taking out composite from flow path
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250144234A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics Inc. RNA for In vivo Transfection with Increased Expression
WO2025129201A1 (en) 2023-12-15 2025-06-19 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
AU771706B2 (en) 1999-07-15 2004-04-01 University Of British Columbia, The Methods and apparatus for preparation of lipid vesicles
CA2491164C (en) * 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
WO2007012191A1 (en) * 2005-07-27 2007-02-01 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
US20120021042A1 (en) 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
KR101452033B1 (en) 2008-12-17 2014-10-21 온코타이레온, 인코포레이티드 Method of making small liposomes
JP5894913B2 (en) * 2009-06-15 2016-03-30 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. DSRNA formulated with lipids targeting the PCSK9 gene
US20130037977A1 (en) * 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US8329080B2 (en) * 2010-04-13 2012-12-11 Ricoh Company, Ltd. Conductive composition, electrophotographic belt, image forming apparatus, and method of manufacturing conductive composition
US9006417B2 (en) * 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CN103906503B (en) * 2011-11-04 2016-12-14 日东电工株式会社 For aseptic prepare lipid-nucleic acid particle be intended for single use system
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP2895146A1 (en) * 2012-09-17 2015-07-22 BIND Therapeutics, Inc. Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
EP3578254B1 (en) * 2013-03-14 2021-08-04 Shoei Chemical Inc. Segmented flow method for the synthesis of nanoparticles
US10195291B2 (en) * 2013-09-24 2019-02-05 Alnylam Pharmaceuticals, Inc. Compositions and methods for the manufacture of lipid nanoparticles
WO2015074085A1 (en) * 2013-11-18 2015-05-21 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
BR112016030852A2 (en) 2014-07-02 2018-01-16 Shire Human Genetic Therapies rna messenger encapsulation
CN106794141B (en) 2014-07-16 2021-05-28 诺华股份有限公司 Method for encapsulating nucleic acids in lipid nanoparticle hosts
LT3221293T (en) * 2014-11-18 2023-03-27 Arcturus Therapeutics, Inc. Ionizable cationic lipid for rna delivery
WO2016149625A1 (en) 2015-03-19 2016-09-22 University Of Connecticut Systems and methods for continuous manufacturing of liposomal drug formulations
US10526284B2 (en) * 2016-12-21 2020-01-07 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US10383952B2 (en) * 2016-12-21 2019-08-20 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
WO2018119163A1 (en) 2016-12-21 2018-06-28 Payne Joseph E Ionizable cationic lipid for rna delivery
SG11202110036RA (en) 2019-03-19 2021-10-28 Arcturus Therapeutics Inc Method of making lipid-encapsulated rna nanoparticles

Also Published As

Publication number Publication date
JP7678758B2 (en) 2025-05-16
CA3133858A1 (en) 2020-09-24
AU2020241756A1 (en) 2021-11-04
US20230398076A1 (en) 2023-12-14
CN113840926A (en) 2021-12-24
KR20220018960A (en) 2022-02-15
WO2020191103A1 (en) 2020-09-24
EP3942050A1 (en) 2022-01-26
IL286424A (en) 2021-10-31
JP2022525540A (en) 2022-05-17
EP3942050A4 (en) 2023-02-22
BR112021018526A2 (en) 2021-11-23
US20200297634A1 (en) 2020-09-24
US12220485B2 (en) 2025-02-11
US11737979B2 (en) 2023-08-29
US20250177305A1 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
IL286424A (en) Method of making lipid-encapsulated rna nanoparticles
GB2627644B (en) Method for the preparation of GalNAc-lipid nanoparticle
EP3243214A4 (en) Structures incorporating and methods of forming metal lines including carbon
EP3182060A4 (en) Apparatus for inspecting shape of metal body, and method for inspecting shape of metal body
EP3405304B8 (en) Gold nanoparticles and ecological method of production
EP3115483A4 (en) Porous metal body and method for producing porous metal body
EP3271288A4 (en) Metal oxide particles and method of producing thereof
EP3615085A4 (en) Rna nanostructures, methods of making, and uses thereof
EP3307679A4 (en) Sodium transition metal silicate and method of forming same
GB2578185B (en) Method of making colloidal platinum nanoparticles
EP4081687A4 (en) Method of construction
HUE068633T2 (en) Method of producing negative electrode
GB201720829D0 (en) Aerofoil and method of manufacture
SG11202101056RA (en) HIGH-Mn STEEL AND METHOD OF PRODUCING SAME
PL3755681T3 (en) Method of 4-boronophenylalanine production
EP3279356A4 (en) Age-hardening steel and method of manufacturing parts using age-hardening steel
SG10201910692SA (en) Photomask blank, and method of manufacturing photomask
GB201905829D0 (en) Method for virus propagation and production
EP3393695A4 (en) Nanoparticle based sand conditioner composition and a method of synthesizing the same
EP3726215A4 (en) Silica nanoparticles for biomarker diagnosis and method for producing same
EP3580056A4 (en) Crane mat and method of manufacture
EP3694809A4 (en) Hydrophobic coatings for metals incorporating anodic and rare-earth oxides and methods of applying same
GB201705864D0 (en) Method of producing ions
EP3389661A4 (en) Composition for reducing frequency of urination, method of making and use thereof
GB202009561D0 (en) Method of making nanoparticles